BBA
CPRX icon

Baker Bros. Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Baker Bros. Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-474,400
Closed -$1.41M – 128
2020
Q3 		$1.41M Sell
474,400
-25,600
-5% -$100K 0.01% 109
2020
Q2 		$2.31M Sell
500,000
-560,714
-53% -$2.52M 0.01% 101
2020
Q1 		$4.08M Sell
1,060,714
-281,188
-21% -$1.15M 0.03% 73
2019
Q4 		$5.03M Hold
1,341,902
– – 0.03% 69
2019
Q3 		$7.13M Sell
1,341,902
-1,217,559
-48% -$6.49M 0.05% 56
2019
Q2 		$9.83M Sell
2,559,461
-340,539
-12% -$1.47M 0.07% 52
2019
Q1 		$14.8M Hold
2,900,000
– – 0.09% 42
2018
Q4 		$5.57M Hold
2,900,000
– – 0.05% 55
2018
Q3 		$11M Sell
2,900,000
-721,962
-20% -$2.26M 0.07% 52
2018
Q2 		$11.3M Sell
3,621,962
-759,110
-17% -$2.3M 0.08% 54
2018
Q1 		$10.5M Sell
4,381,072
-1,471,081
-25% -$4.89M 0.09% 57
2017
Q4 		$22.9M Buy
5,852,153
+750,000
+15% +$2.48M 0.2% 41
2017
Q3 		$12.9M Hold
5,102,153
– – 0.1% 49
2017
Q2 		$14.1M Hold
5,102,153
– – 0.12% 40
2017
Q1 		$9.95M Hold
5,102,153
– – 0.08% 49
2016
Q4 		$5.36M Hold
5,102,153
– – 0.05% 61
2016
Q3 		$5.56M Sell
5,102,153
-20,000
-0.4% -$18K 0.05% 69
2016
Q2 		$3.64M Sell
5,122,153
-376,306
-7% -$303K 0.04% 77
2016
Q1 		$6.43M Sell
5,498,459
-2,777,171
-34% -$4.31M 0.07% 69
2015
Q4 		$20.3M Buy
8,275,630
+939,938
+13% +$2.69M 0.17% 42
2015
Q3 		$22M Hold
7,335,692
– – 0.2% 40
2015
Q2 		$30.3M Sell
7,335,692
-229,770
-3% -$916K 0.27% 37
2015
Q1 		$32.8M Buy
7,565,462
+850,000
+13% +$3.06M 0.27% 32
2014
Q4 		$19.9M Hold
6,715,462
– – 0.2% 37
2014
Q3 		$22.3M Buy
6,715,462
+4,492,409
+202% +$11.7M 0.28% 34
2014
Q2 		$5.62M Buy
2,223,053
+1,653,200
+290% +$3.53M 0.07% 66
2014
Q1 		$1.29M Buy
+569,853
New +$1.19M 0.02% 95

Other funds holding CPRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Baker Bros. Advisors's CPRX Position: Q4 2020 in Review

Baker Bros. Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q4 2020, closing a stake of 474,400 shares — an estimated $1.41M sold.

Baker Bros. Advisors first reported a position in CPRX in Q1 2014 and held it in 27 quarters. The position peaked at $32.8M in Q1 2015. 135 funds tracked by Wall St. Rank hold CPRX as of Q4 2020.

  • Baker Bros. Advisors reported no remaining Catalyst Pharmaceutical position as of Q4 2020 after selling out during the quarter.
  • Baker Bros. Advisors sold 474,400 Catalyst Pharmaceutical shares in Q4 2020, an estimated $1.41M.
  • Baker Bros. Advisors first reported a position in Catalyst Pharmaceutical in Q1 2014 and held it in 27 quarters.
  • Baker Bros. Advisors's Catalyst Pharmaceutical position peaked at $32.8M in Q1 2015.
  • 135 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2020.

Based on Baker Bros. Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.